All In Biotech

Drug Trial Radar · NCT04450693

Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

A Multicenter Phase 3 Confirmatory Trial of Biotherapy Using Cryopreserved Human Umbilical Cord (TTAX01) for Late Stage, Complex Non-healing Diabetic Foot Ulcers (AMBULATE DFU II)

Last checked: Nov 20, 2026Latest source record: Apr 1, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 106 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

106

Actual

Start

Nov 20, 2020

Primary completion

Mar 24, 2025

Study completion Mar 24, 2025

Sponsor

Lead sponsor
BioTissue Holdings, IncIndustry
Sponsor type
Industry
First posted
Jun 29, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

It is hypothesized that application at 4-week or greater intervals of the human placental umbilical cord tissue TTAX01 to the surface of a well debrided, complex diabetic foot ulcer (DFU) will, with concomitant management of infection, result in a higher rate of wounds showing complete healing within 25 weeks of initiating therapy, compared with standard care alone. This second confirmatory Phase 3 study examines a population of diabetic foot ulcer patients having adequate perfusion, with or without neuropathy, and a high suspicion of associated osteomyelitis in a complex, high grade wound.

Conditions

  • Diabetic Foot Infection
  • Non-healing Wound
  • Non-healing Diabetic Foot Ulcer

Interventions

  • TTAX01Biological

    TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).

  • Standard careOther

    Standard care is defined in this protocol to consist of the following: * Debridement; * Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited; * Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate; * A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin; * Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and, * Appropriate use of systemic antibiotics.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete wound healingTime frame: over 25 weeks

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • LakeView Clinical Research

    Guntersville, Alabama

  • Banner University Medical Center Tucson

    Tucson, Arizona

  • Clemente Clinical Research

    Los Angeles, California

  • VA Northern California Health Care System

    Mather, California

  • CureCentric

    Palmdale, California

  • PIH Health

    Whittier, California

  • Midland Florida Clinical Research Center

    DeLand, Florida

  • Delray Physician Care Center

    Delray Beach, Florida

  • Gateway Clinical Trials, LLC

    O'Fallon, Illinois

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Reno Orthopedic Clinic

    Reno, Nevada

  • Curalta Foot and Ankle

    Westwood, New Jersey

  • Cutting Edge Research, LLC

    Circleville, Ohio

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Advantage Foot Care of Houston

    Houston, Texas

  • Biolife Genetics Research

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.